1 / 77

VOGT-KOYANAGI-HARADA DISEASE

VOGT-KOYANAGI-HARADA DISEASE. AHMED M. ABU EL-ASRAR, MD, PhD. Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia Dr. Nasser Al-Rashid Research Chair in Ophthalmology. VKH Disease. Multisystem disease

clark
Télécharger la présentation

VOGT-KOYANAGI-HARADA DISEASE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. VOGT-KOYANAGI-HARADADISEASE AHMED M. ABU EL-ASRAR, MD, PhD Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia Dr. Nasser Al-Rashid Research Chair in Ophthalmology

  2. VKH Disease • Multisystem disease • Chronic, bilateral, granulomatous panuveitis associated with central nervous system, auditory and integumentary manifestations Moorthy et al: SurvOphthalmol 1995; 39:265 (review) Read et al: Am J Ophthalmol 2001;131:647

  3. VKH Disease Epidemiology • Individuals with a predisposing genetic background. • Ethnic groups with more heavily pigmented skin. • Asians, Native Americans, Hispanics, Asian Indians, Middle Easterners.

  4. VKH Disease Epidemiology • Genetic background rather than degree of skin pigmentation. • Women more than men. • 3rd – 4th decade. • Pediatric age group. Read et al: CurrOpinOphthalmol 2000;11:437 (review) Abu El-Asrar et al: Eye 2008;22:1124 Martin et al: Retina 2010 Feb 17. [Epub ahead of print]

  5. VKH Disease Etiology and Pathogenesis • Remains unknown. • T-lymphocyte mediated autoimmunity directed against one or more antigens found on or associated with melanocytes found in eye, skin and hair, inner ear, CNS. Okada et al: Graefe’s Arch Clin Exp Ophthalmol 1996;234:359

  6. VKH Disease Etiology and Pathogenesis • Tyrosinase family proteins are enzymes for melanin formation and are expressed in melanocytes. • T-lymphocytes from VKH disease patients proliferate in response to tyrosinase, TRP1 or TRP2. • Immunization of Lewis rats with tyrosinase, TRP1 or TRP2 produced an inflammatory disease that resembled VKH disease with skin lesions and meningitis. Yamaki et al: J Immunol 2000;165:7323 Yamaki et al: Exp Eye Res 2000;71:361

  7. VKH Disease Etiology and Pathogenesis • Th cells from peripheral blood of VKH patients produce predominantly Th1 cytokines (IFN-gamma, IL-2) especially when stimulated • T-cell clones specific to tyrosinase family proteins established from peripheral blood mononuclear cells of patients with VKH disease showed proliferative responses to tyrosinase and/or TRP1 and produced Th1-type cytokines. Imai et al: Curr Eye Res 2001;22:312 Gocho et al: Invest Ophthalmol Vis Sci 2001;42:2004

  8. VKH Disease Etiology and Pathogenesis • IL-23 stimulated production of IL-17 by CD4+ T cells may be responsible for the development of VKH disease. Fang and Yang: Curr Eye Res 2008;33:517

  9. VKH Disease Etiology and Pathogenesis • VKH-like disease in patients treated with interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection. Al-Muammar et al: IntOphthalmol 2010 Feb 23. [Epub ahead of print] Sene et al: World J Gastroenterol 2007;13:3137 Touitou et al: Am J Ophthalmol 2005;140:949 Papastathopoulos et al: J Infect 2006;52:e59 Kasahara et al: J Gastroenterol 2004;39:1106 Sylvestre et al: J Viral Hepat 2003;10:467

  10. VKH Disease Pathology • Granulomatous panuveitis. • Lymphocytes, epitheloid cells, few plasma cells, multinucleated giant cells. • Epitheloid cells and giant cells contain melanin pigment.

  11. VKH Disease Pathology • Dalen-Fuchs’ nodules: Lymphocytes, epitheloid cells, pigment-laden macrophages, altered and/or proliferated RPE cells. • Melanocytes disappear from choroid. Perry and Font: Am J Ophthalmol 1977;83:242 Inomata and Rao: Am J Ophthalmol 2001;131:607

  12. VKH Disease Genetic Factors • Certain racial groups. • Immunogenetic predisposition. • Strong association with HLA-DR4 and HLA-DRw53 with the most significant risk allele being HLA-DRB1*0405. • Causative pathogenic antigen binds with HLA-DRB1*0405 molecule which presents the antigen to T cells to activate them. Fang and Wang: Curr Eye Res 2008;33:517 (review). Read et al: CurrOpinOphthalmol 2000;11:437 (review). Yamaki et al: IntOphthalmolClin 2002;42:13 (review).

  13. VKH Disease Genetic Factors • VKH disease in monozygotic twins • Familial VKH disease • Familial cases shared HLA-DR4 Itho et al: IntOphthalmol 1992;16:49 Rutzen et al: Am J Ophthalmol 1995;119:239 Sonoda et al: Jpn J Ophthalmol 1999;43:113

  14. VKH Disease Clinical FeaturesExtraocular Manifestations Integumentary Manifestations • Sensitivity of hair and skin to touch (early in prodromal phase). • Poliosis, vitiligo, alopecia (during convalescent stage). • Ethnic groups may manifest varying systemic symptoms.

  15. VKH Disease Clinical FeaturesExtraocular Manifestations Neurologic Manifestations • Most common during prodromal stage. • Neck stiffness, headache, confusion. • Occasionally focal neurologic signs. • CSF pleocytosis.

  16. VKH Disease Clinical FeaturesExtraocular Manifestations Auditory Manifestations • May be presenting problem • Sensorineural hearing loss usually involves higher frequencies • Tinnitus • Vertigo • May cause permanent hearing loss

  17. VKH Disease Clinical FeaturesAuditory Manifestations

  18. VKH Disease Clinical Course 4 phases • Prodromal • Acute uveitic • Convalescent or chronic • Chronic recurrent

  19. VKH Disease Clinical Course Prodromal Phase: • Mimics viral illness • Neurologic and auditory manifestations • Few days • Headache, orbital pain, stiff neck, malaise, abdominal pain, nausea, fever, vertigo, tinnitus • Cranial nerve palsies, optic neuritis (rare) • CSF pleocytosis

  20. VKH Disease Clinical Course Acute Uveitic Phase: • Bilateral in 70% of patients, delay of 1-3 days before 2nd eye becomes involved in 30%. In a few cases this interval may last up to 10 days. • Hallmark is bilateral multifocal exudative retinal detachments, hyperemia and edema of the optic disc.

  21. VKH Disease Clinical Course Acute Uveitic Phase: (cont.). • Yellow-white lesions at level of RPE beneath serous RD. • Thickening of posterior choroid manifested by elevation of peripapillary retino-choroid layer. • Retinal edema in posterior pole. • Peripheral well-circumscribed yellow-white lesions (clinical equivalent of Dalen-Fuchs’ nodules).

  22. VKH Disease Clinical Course Acute Uveitic Phase: (cont.) • No inflammation of the anterior segment or mild to moderate nongranulomatous anterior uveitis if the disease is not well controlled with appropriate treatment during the first two weeks. Fang and Yang: Curr Eye Res 2008;33:517 (review)

  23. VKH Disease Clinical Course Acute Uveitic Phase: (cont.). • Shallow anterior chamber • Elevated IOP • Acute angle closure glaucoma

  24. VKH Disease Clinical Course Convalescent Phase: • Integumentary and uvea depigmentation. • Perilimbal vitiligo (Sugiura’s sign). • Fundus exhibits an orange-red discoloration (“sunset-glow” fundus).

  25. VKH Disease Clinical Course Convalescent Phase: (cont.) • Multiple small yellow well-circumscribed areas of chorioretinal atrophy representing regressed Dalen-Fuchs’ nodules. • RPE clumping or migration. • Pigmented demarcation lines.

  26. VKH Disease Clinical Course Chronic Recurrent Phase: • Acute episodes of granulomatous anterior uveitis with development of iris nodules • Recurrent posterior uveitis is distinctly uncommon • Complications are seen in this phase

  27. VKH Disease Clinical Course Chronic Recurrent Phase: • Patients with recurrent VKH disease had a more intensive inflammation in the anterior segment and long-lasting dysfunction of the blood-aqueous barrier than those with initial onset VKH disease. Fang et al: Br J Ophthalmol 2008;92:182

  28. VKH Disease Laboratory Investigations Diagnosis is made by clinical examination and ancillary test findings • Fluorescein angiography • Indocyanine green angiography • Ultrasonography • Optical coherence tomography • Multifocal electroretinograms • Lumbar puncture

  29. VKH Disease Laboratory Investigations Ultrasonography: • Diffuse low to medium thickening of choroid. • Overlying exudative RD.

  30. VKH Disease Laboratory Investigations OCT Useful in monitoring resolution of exudative retinal detachment On presentation 4 weeks after systemic corticosteroid

  31. VKH Disease Laboratory Investigations Multifocal Electroretinogram • May be useful in detecting early retinal damage. • Macular function is severely impaired in patients with active uveitis. • Treatment with immunosuppressive agents leads to delayed but limited recovery of macular function. • May be useful in guiding therapy. Chee et al: Graefe’s Arch Clin Exp Ophthalmol 2005; 243:785. Yang et al: Am J Ophthalmol 2008; 146:767.

  32. VKH Disease Retinal functional changes measured by microperimetry after immunosuppressive therapy • Patients displayed a markedly decreased BCVA, fixation stability and mean retinal sensitivity at baseline. • BCVA and fixation stability recovered earlier, faster and better than mean retinal sensitivity. • At final follow-up, retinal sensitivity was significantly reduced even in eyes with full recovery of BCVA. • Subclinical macular dysfunction is a permanent damage in VKH disease. Abu El-Asrar et al: Eur J Ophthalmol 2012; 22:368

  33. VKH Disease Retinal functional changes measured by microperimetry after immunosuppressive therapy

  34. VKH Disease Laboratory Investigations Lumbar Puncture: • Rarely necessary in a typical case. • CSF pleocytosis (mostly lymphocytes). • Transient and resolves within 8 weeks.

  35. VKH Disease Laboratory Investigations Lumbar Puncture: • Frequency of CSF pleocytosis and the number of cells in CSF at disease onset were significantly higher in patients who eventually developed sunset glow fundus. Keino et al: Am J Ophthalmol 2006; 141:1140.

  36. VKH Disease Complications • Cataract • Secondary glaucoma • Choroidal neovascular membranes • Subretinal fibrosis • Severe chorioretinal atrophy • Significantly associated with longer duration of disease and greater numbers of recurrences. Read et al : Am J Ophthalmol 2001;131:599. Sonoda et al: Jpn J Ophthalmol 1999;43:113.

  37. VKH Disease Complications • Significantly associated with older age and more severe disease at presentation. Al-Kharashi, Abu El-Asrar: IntOphthalmol 2007;27:201

  38. VKH Disease Therapy • Should be prompt and aggressive. • Systemic corticosteroids are mainstay of therapy. • 1-1.5 mg/kg/day of oral Prednisone (single morning-after-breakfast dose). • For 6-12 months with slow gradual tapering during this time. • Hospitalization with careful follow-up.

  39. VKH Disease Therapy • Intravenous high-dose pulse steroid therapy (1g/day of Methylprednisolone given for 3 days) followed by oral Prednisone (1 mg/kg/day). • Topical Prednisone 1% solution and cycloplegics for anterior uveitis. • Patients adequately treated with corticosteroids have a fair visual prognosis. • Recurrences are associated with rapid or early decrease in steroid doses.

  40. VKH Disease Therapy • Such treatment may shorten duration of disease, prevent progression into chronic stage, reduce incidence of extraocular manifestations. • Failure to prescribe proper corticosteroid therapy in initial phase may lead to chronic recurrent uveitis that may result in severe visual loss due to extensive chorioretinal atrophy. Sonoda et al: Jpn J Ophthalmol 1999;43:113.

  41. VKH Disease Therapy • Final VA of 20/20 was significantly associated with use of systemic corticosteroids for longer than 9 months and slow tapering. • Recurrent inflammation was significantly associated with rapid tapering of systemic corticosteroids. Al-Kharashi, Abu El-Asrar: IntOphthalmol 2007;27:201

  42. VKH Disease Therapy • Patients treated initially with immunomodulatory drugs (mycophenolate mofetil, cyclosporine A, azathioprine, and methotrexate) combined with corticosteroids had a better visual outcome than those who received corticosteroids as monotherapy. • Immunomodulatory therapy combined with corticosteroids should be considered as first-line therapy for patients with VKH. Paredes et al: OculImmunolInflamm 2006;14:87 Kim and Yu: OculImmunolInflamm 2007;15:381 Abu El-Asrar, et al: ActaOphthalmol 2012;90:e603

  43. VKH Disease The outcomes of mycophenolate mofetil combined with systemic corticosteroids in acute uveitis associated with VKH disease • Use of mycophenolate mofetil as first-line therapy combined with systemic corticosteroids is safe and effective in the treatment of acute uveitis associated with VKH disease. • It has marked corticosteroid-sparing effect and significantly reduced development of chronic recurrent inflammation and late complications and significantly improved visual outcome. Abu El-Asrar et al: ActaOphthalmol 2012; 90:e603

  44. VKH Disease Prognosis • Visual prognosis is generally favorable. • 87.5% achieved V.A. of ≥20/40. • High-dose systemic corticosteroids for >9 months with slow tapering significantly improves the prognosis and decreases risk of recurrence. • Age older than 18 years is significantly associated with the development of complications. • Visual prognosis is generally favorable in children. Al-Kharashi, Abu El-Asrar: IntOphthalmol 2007;27:201 Abu El-Asrar et al: Eye 2008;22:1124

  45. VKH Disease Prognostic factors for clinical outcomes in patients treated with high-dose corticosteroids • Poor visual acuity and severe anterior segment inflammation at presentation are significantly associated with a worse outcome. • Chronic recurrent disease is significantly associated with more severe anterior segment inflammation and less exudative retinal detachment at presentation, more ocular complications and a worse visual outcome compared with initial-onset disease. • Use of immunomodulatory therapy as first-line therapy combined with systemic corticosteroids significantly improved clinical outcomes. Abu El-Asrar et al: ActaOphthalmol. In press.

  46. Sympathetic Ophthalmia Ahmed M. Abu El-Asrar, MD, PhD

  47. Sympathetic Ophthalmia • Rare bilateral granulomatous panuveitis that occurs as a complication of a penetrating injury that involves the uvea of one eye. • Accidental trauma or surgery. • Injured eye is referred to as the exciting eye and fellow eye as the sympathizing eye.

  48. Sympathetic Ophthalmia Incidence • In 0.1% to 0.3% of patients after accidental trauma. • In 0.015% of patients following ocular surgery. • 5.8% and 0.67% after noncontact and contact Nd:YAG cyclotherapy, respectively. Allen: JAMA 1969;209:1090 Liddy, Stuart: Can J Ophthalmol 1972;7:157 Gass: Am J Ophthalmol 1982;93:552 Lam et al: Ophthalmology 1992;99:1818

  49. Sympathetic Ophthalmia Incidence Role of ocular surgery • Sole cause in: • 45% of cases (Gass: Am J Ophthalmol 1982;93:552) • 17% of cases(Hakin et al: Eye 1992;6:453) • 28% of cases(Chan et al: Arch Ophthalmol 1995;113:597) • 56% of cases(Kilmartin et al: Br J Ophthalmol 2000;84:259) • 70% of cases (Su and Chee: Graefes’ Arch Clin Exp Ophthalmol 2006;244:243) • 38% of cases(Galor et al: Am J Ophthalmol 2009;148:704)

  50. Sympathetic Ophthalmia Incidence Role of ocular surgery • Ocular surgery, particularly retinal surgery, is now a greater risk than accidental trauma. • Risk of one in 1152 retinal surgical procedures. Kilmartin et al: Br J Ophthalmol 2000;84:259 Su and Chee: Graefe’s Arch Clin Exp Ophthalmol 2006;244:243 Kilmartin et al: Br J Ophthalmol 2000;84:448

More Related